Alison Moore
Director/Board Member presso CODEXIS, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Attualmente, Alison Moore occupa la posizione di direttore tecnico presso Allogene Therapeutics, Inc. La dott.ssa Moore è anche nel consiglio di amministrazione di Codexis, Inc. In passato la dott.ssa Moore ha occupato la posizione di vicepresidente senior dello sviluppo dei processi presso Amgen, Inc. e di direttore di chimica, produzione e controlli presso Genentech, Inc. Alison Moore ha ricevuto un dottorato e una laurea presso l'Università di Manchester.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
22/03/2023 | 670 173 ( 0.40% ) | 3 M $ | 31/03/2024 | |
CODEXIS, INC.
0.10% | 13/06/2023 | 68 576 ( 0.10% ) | 239 330 $ | 31/03/2024 |
Posizioni attive di Alison Moore
Società | Posizione | Inizio |
---|---|---|
CODEXIS, INC. | Director/Board Member | 16/06/2020 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Precedenti posizioni note di Alison Moore
Società | Posizione | Fine |
---|---|---|
ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28/04/2023 |
AMGEN INC. | Corporate Officer/Principal | 01/06/2018 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 01/01/2006 |
Formazione di Alison Moore
The University of Manchester | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
AMGEN INC. | Health Technology |
CODEXIS, INC. | Process Industries |
ALLOGENE THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
- Borsa valori
- Insiders
- Alison Moore